Key result
Gene therapy strategies targeting inflammation in atrial fibrillation represent an innovative management approach, with emerging molecular targets and delivery platforms currently under investigation.
Why the study?
Inflammatory signaling is altered in AF, highlighting the need to evaluate gene therapy strategies targeting inflammation as an innovative management approach.
Gene therapy targeting inflammation represents an emerging and innovative strategy for the management of atrial fibrillation, with ongoing research into vectors, delivery platforms, and molecular targets.
Gene therapy for AF inflammation remains preclinical; leaves open the need for targeted vector trials before any clinical consideration.
)-handling machinery, functional gap junctions, and efficient inflammatory signaling, known to be altered in AF. With an emphasis on the importance of gene therapy strategies targeting inflammation, this narrative review aims to: i) highlight the rationale and clinical relevance of gene therapy as an innovative strategy for the management of AF; ii) evaluate current knowledge regarding gene therapy vectors and delivery platforms applicable to cardiology and AF; iii) review emerging molecular targets explored in the context of AF gene therapy; and iv) identify promising gene-based therapeutic candidates, with a particular focus on inflammation-related pathways in AF.
No takes yet. Share an insight, caveat, or question.
Zemmouchi et al. (2026) conducted a review in Atrial fibrillation. Gene therapy targeting inflammation was evaluated. Gene therapy strategies targeting inflammation in atrial fibrillation represent an innovative management approach, with emerging molecular targets and delivery platforms currently under investigation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: